Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has revealed that Scientia Clinical Research has completed cohort dosing of both male and female participants in its Phase 1/2 UTI clinical trial evaluating RECCE® 327 at faster infusion rates and ahead of schedule.
R327 was shown to be safe and well tolerated at two faster infusion rates of 2,500mg, with an independent safety committee reviewing complete cohort dosing data, expected to recommend going ahead, with recruitment well underway.
Highlighting the significance of this milestone, Recce CEO James Graham said, “R327 via two faster infusion rates of 2,500mg across male and female subjects continues to be shown as safe and well tolerated.
“Completing dosing well ahead of schedule is a welcomed confirmation that we are on track to achieving study objectives."
Recce’s anti-infective pipeline
Recce is developing a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
The company’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives, which are:
- RECCE® 327, an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms;
- RECCE® 435, an orally administered therapy for bacterial infections; and
- RECCE® 529, for viral infections.
Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.